Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia

A. A. Avagimyan; L. V. Kakturskiy

Siberian Journal of Clinical and Experimental Medicine

ISSN 2713-2927 (Print)
ISSN 2713-265X (Online)

User

eng | рус

Siberian Journal of Clinical and Experimental Medicine

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Avagimyan A.A., Kakturskiy L.V. Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia. Siberian Journal of Clinical and Experimental Medicine. 2022;37(2):105-111. (In Russ.) https://doi.org/10.29001/2073-8552-2022-37-2-105-111

Views PDF (Rus): 324

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2713-2927 (Print)
ISSN 2713-265X (Online)

Internal Medicine

Radiology, Nuclear Medicine and Imaging

Notifications

* not an advertisement

Indexing Databases

* not an advertisement

Editor-in-Chief

Rostislav S. Karpov

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

A. A. Avagimyan
Yerevan State Medical University named after M. Heratsi; A.P. Avtsyn Research Institute of Human Morphology
Armenia

Ashot A. Avagimyan, M.D., Assistant Professor, Department of Pathological Anatomy and Clinical Morphology; Postgraduate Student

2, Koryun str., Yerevan, 0025, Republic of Armenia

3, Tsyurupa str., Moscow, 117418, Russian Federation

L. V. Kakturskiy
A.P. Avtsyn Research Institute of Human Morphology
Russian Federation

Lev V. Kakturskiy, Dr. Sci. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Scientific Director, President of the Russian Society of Pathology

3, Tsyurupa str., Moscow, 117418, Russian Federation

Username
Password
	Remember me

User

Siberian Journal of Clinical and Experimental Medicine

For citations:

Cookies policy